UBS has upgraded CSL (ASX:CSL) to Buy from Neutral, citing higher profit growth forecasts for FY14

Livewire Equities


UBS has upgraded CSL (ASX:CSL) to Buy from Neutral, citing higher profit growth forecasts for FY14. According to the broker, CSL has forgone any 2013 price increase in the US and so the company's Privigen IVIG is currently priced 9% lower than its US peers but higher than the rest of the world. UBS estimates the company is planning around 12% FY14 volume growth, however, if it grows US volumes faster, a 40% price arbitrage can be achieved. As such, the target price for CSL has been raised from $70 to $75 (current price $64.53) with an expected return of 16%. Based on the last closing share price, the stock's estimated price-to-earnings ratio is 21.12.

2 topics

Livewire Equities
Livewire Equities

The Livewire Equities feed brings you a range of insights that relate to Australian equities


No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Please sign in to comment on this wire.

trending on livewire
Get the best of Livewire by signing up to our popular daily newsletter